{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:05:09Z","timestamp":1779800709801,"version":"3.53.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00105-026-05672-8","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:28:04Z","timestamp":1776155284000},"page":"406-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erfolgreicher Einsatz von Anifrolumab bei chronisch diskoidem Lupus erythematodes","Successful management of chronic discoid lupus erythematosus with anifrolumab"],"prefix":"10.1007","volume":"77","author":[{"given":"Inga","family":"Hansen-Abeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Abeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Christolouka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"5672_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.941003","volume":"9","author":"A Verdelli","year":"2022","unstructured":"Verdelli\u00a0A, Corra\u00a0A, Mariotti\u00a0EB, Aimo\u00a0C, Ruffo di Calabria\u00a0V, Volpi\u00a0W et\u00a0al (2022) An update on the management of refractory cutaneous lupus erythematosus. Front Med (Lausanne) 9:941003","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"5672_CR2","first-page":"426","volume":"21","author":"C G\u00fcnther","year":"2023","unstructured":"G\u00fcnther\u00a0C, Wenzel\u00a0J (2023) Lupus erythematodes. J\u00a0Dtsch Dermatol Ges 21(4):426\u2013431","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"5672_CR3","first-page":"1236","volume":"19","author":"M Worm","year":"2021","unstructured":"Worm\u00a0M, Zidane\u00a0M, Eisert\u00a0L, Fischer-Betz\u00a0R, Foeldvari\u00a0I, Gunther\u00a0C et\u00a0al (2021) S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 1: Classification, diagnosis, prevention, activity scores. J\u00a0Dtsch Dermatol Ges 19(8):1236\u20131247","journal-title":"J Dtsch Dermatol Ges"},{"issue":"20","key":"5672_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042518","volume":"104","author":"R Aljohani","year":"2025","unstructured":"Aljohani\u00a0R (2025) Anifrolumab for refractory discoid lupus: Two case reports of successful outcomes in Saudi Arabia. Medicine (Baltimore) 104(20):e42518","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"5672_CR5","first-page":"1371","volume":"19","author":"M Worm","year":"2021","unstructured":"Worm\u00a0M, Zidane\u00a0M, Eisert\u00a0L, Fischer-Betz\u00a0R, Foeldvari\u00a0I, Gunther\u00a0C et\u00a0al (2021) S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 2: Therapy, risk factors and other special topics. J\u00a0Dtsch Dermatol Ges 19(9):1371\u20131395","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"5672_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1177\/09612033251337130","volume":"34","author":"S Manzi","year":"2025","unstructured":"Manzi\u00a0S, S\u00e1nchez-Guerrero\u00a0J, Yokogawa\u00a0N, Wenzel\u00a0J, Ocran-Appiah\u00a0JC, Harris\u00a0JH et\u00a0al (2025) The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis. Lupus 34(7):666\u2013678","journal-title":"Lupus"},{"issue":"4","key":"5672_CR7","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","volume":"4","author":"EF Morand","year":"2022","unstructured":"Morand\u00a0EF, Furie\u00a0RA, Bruce\u00a0IN, Vital\u00a0EM, Dall\u2019Era\u00a0M, Maho\u00a0E et\u00a0al (2022) Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP\u20111 and TULIP\u20112 trials. Lancet Rheumatol 4(4):e282\u2013e292","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"5672_CR8","doi-asserted-by":"publisher","first-page":"T55","DOI":"10.1016\/j.ad.2024.10.008","volume":"116","author":"D Martin-Torregrosa","year":"2025","unstructured":"Martin-Torregrosa\u00a0D, Mansilla-Polo\u00a0M, Morgado-Carrasco\u00a0D (2025) [Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses. Actas Dermosifiliogr 116(1):T55\u2013T67","journal-title":"Actas Dermosifiliogr"},{"key":"5672_CR9","doi-asserted-by":"crossref","unstructured":"Paolino G, Ramirez GA, Calabrese C, Moroni L, Bianchi VG, Bozzolo EP, et\u00a0al. Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A\u00a0Monocentric Experience and Review of the Current Literature. Biomedicines. 2023;11(11).","DOI":"10.3390\/biomedicines11112904"},{"key":"5672_CR10","doi-asserted-by":"crossref","unstructured":"Loricera J, Bejerano C, Estebanez A, Garcia I, Mohammad N, Sanmartin M, et\u00a0al. Anifrolumab for Nonsystemic Cutaneous Lupus Erythematosus: Clinical Experience, Immunologic Insights, and Review of the Literature. J\u00a0Clin Med. 2025;14(16).","DOI":"10.3390\/jcm14165683"},{"issue":"5","key":"5672_CR11","volume":"17","author":"AG Dykema","year":"2025","unstructured":"Dykema\u00a0AG, Vodusek\u00a0Z, Karagenova\u00a0R, Krieger\u00a0A, Timlin\u00a0H (2025) Combination Therapy With Voclosporin and Anifrolumab in Two Patients With Lupus Nephritis and Discoid Lupus Erythematosus. Cureus 17(5):e83337","journal-title":"Cureus"},{"issue":"5","key":"5672_CR12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40262-023-01238-2","volume":"62","author":"W Tang","year":"2023","unstructured":"Tang\u00a0W, Tummala\u00a0R, Almquist\u00a0J, Hwang\u00a0M, White\u00a0WI, Boulton\u00a0DW et\u00a0al (2023) Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clin Pharmacokinet 62(5):655\u2013671","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"5672_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40257-023-00774-8","volume":"24","author":"D Niebel","year":"2023","unstructured":"Niebel\u00a0D, de Vos\u00a0L, Fetter\u00a0T, Bragelmann\u00a0C, Wenzel\u00a0J (2023) Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions. Am J Clin Dermatol 24(4):521\u2013540","journal-title":"Am J Clin Dermatol"},{"key":"5672_CR14","doi-asserted-by":"crossref","unstructured":"Chasset F, Teboul A. Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management. J\u00a0Eur Acad Dermatol Venereol. 2025.","DOI":"10.1111\/jdv.70186"},{"key":"5672_CR15","unstructured":"Werth VP, Merola JF, Furie R, Kalunian K, van Vollenhoven RF, Romero-Diaz J, et\u00a0al. Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase\u00a02 LILAC study. J\u00a0Eur Acad Dermatol Venereol. 2026."}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05672-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05672-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05672-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:26:05Z","timestamp":1779798365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05672-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5672"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05672-8","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"I.\u00a0Hansen-Abeck, F.\u00a0Abeck, M.\u00a0Christolouka und S.W.\u00a0Schneider geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}